ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
05/07/2026
Back to search
Official data from USPTO
S SCITARIS BIOPHARMA STRATEGY
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
31
Latest update
05/09/2026
Trademark type
Combined
Nice classes
35, 42, 44
Filing date
07/05/2021
Registration date
08/02/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/02/2022
Last transaction
05/09/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
98
Owner location
DE
Examiner
LAMONT, JOHN CHRISTOPHER
Law office
N50
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the "SCITARIS BIOPHARMA STRATEGY" in black stylized characters to the right of a green design of a circular maze with an "S" at its center. The color white represents background and/or transparent areas and is not part of the mark.
Holders and representatives
Holders
Scitaris GmbH & Co. KG
Scitaris GmbH
Representatives
Frank D Taff FRANK D. TAFF, J.D.
Technical classification
Nice Classes
Class 35Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 35
Advertising; business management; business administration
Class 42
Scientific and technological servicesresearch and design in the field of pharmaceuticals; medical device design services; product development; pharmaceutical research and development; pharmaceutical product evaluation; consultancy relating to pharmaceutical research and development; consultancy in the field of pharmaceutical research; medical and pharmacological research services; quality control for others in the field of pharmaeeuticals; authentication services being inspection of pharmaceuticals
Class 44
Medical services; pharmacy advice; medical consultancy and information services relating to medical products
Publications
History of USPTO decisions and trademark events.
31 publications found
NREP
NEW REPRESENTATIVE AT IB RECEIVED
03/12/2026
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
12/05/2022
FICS
FINAL DISPOSITION NOTICE SENT TO IB
11/10/2022
FIMP
FINAL DISPOSITION PROCESSED
11/10/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
11/02/2022
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/02/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
08/02/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/17/2022
PUBO
PUBLISHED FOR OPPOSITION
05/17/2022
GPNX
NOTIFICATION PROCESSED BY IB
05/16/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/27/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
04/27/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/27/2022
RFNT
REFUSAL PROCESSED BY IB
04/18/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/14/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
04/13/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
04/13/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
04/13/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
04/13/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/02/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/01/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/01/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/28/2022
RFRR
REFUSAL PROCESSED BY MPU
03/28/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/26/2022
CNRT
NON-FINAL ACTION WRITTEN
03/25/2022
DOCK
ASSIGNED TO EXAMINER
03/24/2022
MAFR
APPLICATION FILING RECEIPT MAILED
01/08/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/04/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/30/2021
Continuous trademark protection
Get notified about every new filing that threatens S SCITARIS BIOPHARMA STRATEGY or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.